Related Experiment Video
Updated: Sep 17, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Dusp1 in osteolytic diseases-mechanisms and therapeutic potential
Boyu Liu1,2, Ming Lei1, Baicheng Wan1
1Department of Spine Osteopathia, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, No. 6, Shuangyong Road, Nanning, 530021, Guangxi, China.
Abstract:
Osteolytic diseases are a significant and escalating global public health issue, driven by the acceleration of population aging and the rising incidence of degenerative, metabolic, and neoplastic diseases. The primary therapeutic strategy for osteolytic diseases is to suppress the bone resorption activity of osteoclasts. Dusp1 is a member of the serine/threonine inducible nuclear phosphatase family and has significant anti-inflammatory effects. In this study, Dusp1 overexpression was induced via lentiviral transfection. We found that Dusp1 antagonized RANKL stimulation, mediated the MAPK signaling pathway, and downregulated the key downstream transcription factors c-FOS and NFATc1, thereby reducing the expression of osteoclast-specific genes. Furthermore, Dusp1 reduced the number and activity of osteoclasts both in vivo and in vitro, leading to a diminished bone resorption function. In addition, the results of animal experiments demonstrated that Dusp1 protected mice from LPS-induced skull osteolysis. Overall, our study reveals that Dusp1 suppresses osteoclast formation and activity by downregulating the MAPK/c-FOS/NFATc1 signaling pathway. These findings suggest the potential of Dusp1 to protect against osteolytic diseases.
Insights
Dual specificity phosphatase 1 (Dusp1) suppresses osteoclast formation and activity by inhibiting the MAPK/c-FOS/NFATc1 pathway, offering potential protection against osteolytic diseases.
Area of Science:
- Biomedical Science
- Molecular Biology
- Immunology
Background:
- Osteolytic diseases pose a growing global health challenge due to aging populations and increased incidence of related conditions.
- Current treatments focus on inhibiting osteoclast activity, the primary drivers of bone resorption.
- Dusp1, a nuclear phosphatase with anti-inflammatory properties, is investigated for its role in osteoclast regulation.
Purpose of the Study:
- To investigate the effect of Dusp1 overexpression on osteoclast formation and activity.
- To elucidate the molecular mechanisms by which Dusp1 influences osteoclastogenesis.
- To evaluate the therapeutic potential of Dusp1 in osteolytic disease models.
Main Methods:
- Dusp1 overexpression was achieved using lentiviral transfection.
- The study analyzed Dusp1's interaction with RANKL signaling and the MAPK pathway.
- Osteoclast number, activity, and bone resorption were assessed in vitro and in vivo.
- An LPS-induced skull osteolysis mouse model was used for animal experiments.
Main Results:
- Dusp1 overexpression antagonized RANKL stimulation and modulated the MAPK signaling pathway.
- Dusp1 downregulated key transcription factors c-FOS and NFATc1, reducing osteoclast-specific gene expression.
- In vitro and in vivo experiments showed Dusp1 reduced osteoclast number and activity, impairing bone resorption.
- Animal studies demonstrated Dusp1 conferred protection against LPS-induced skull osteolysis.
Conclusions:
- Dusp1 effectively suppresses osteoclast formation and activity by downregulating the MAPK/c-FOS/NFATc1 signaling pathway.
- Dusp1 exhibits protective effects against osteolytic bone disease.
- Dusp1 represents a potential therapeutic target for managing osteolytic diseases.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...